Abstract:Pyrrolizidine alkaloids (PAs) are natural toxins widely distributed in plants. The toxic potencies of different PAs vary significantly. PAs are mono- or diesters of necine acids with a necine base. On the basis of the necine bases, PAs are classified into three types: retronecine-type, otonecine-type, and platynecine-type. Hepatotoxic PAs contain an unsaturated necine base. PAs exert hepatotoxicity through metabolic activation by hepatic cytochromes P450s (CYPs) to generate reactive intermediates which form pyrrole-protein adducts. These adducts provide a mechanism-based biomarker to assess PA toxicity. In the present study, metabolic activation of 12 PAs from three structural types was investigated first in mice to demonstrate significant variations in hepatic metabolic activation of different PAs. Subsequently, the structural and enzymatic factors affecting metabolic activation of these PAs were further investigated by using human liver microsomes and recombinant human CYPs. Pyrrole-protein adducts were detected in the liver and blood of mice and the in vitro systems treated with toxic retronecine-type and otonecine-type PAs having unsaturated necine bases but not with a platynecine-type PA containing a saturated necine base. Retronecine-type PAs produced more pyrrole-protein adducts than otonecine-type PAs with similar necine acids, demonstrating that the structure of necine base affected PA toxic potency. Among retronecine-type PAs, open-ring diesters generated the highest amount of pyrrole-protein adducts, followed by macrocyclic diesters, while monoesters produced the least. Only CYP3A4 and CYP3A5 activated otonecine-type PAs, while all 10 CYPs studied showed the ability to activate retronecine-type PAs. Moreover, the contribution of major CYPs involved also varied significantly among retronecine-type PAs. In conclusion, our findings provide a scientific basis for predicting the toxicities of individual PAs in biological systems based on PA structural features and on the pattern of expression and the selectivity of the CYP isoforms present.

Hepatotoxicity of Pyrrolizidine Alkaloid Compound Intermedine: Comparison with Other Pyrrolizidine Alkaloids and Its Toxicological Mechanism

Pyrrolizidine Alkaloids: an Update on Their Metabolism and Hepatotoxicity Mechanism

Diagnosis, toxicological mechanism, and detoxification for hepatotoxicity induced by pyrrolizidine alkaloids from herbal medicines or other plants

Identification Of Toxic Pyrrolizidine Alkaloids And Their Common Hepatotoxicity Mechanism

Proteomic Characterization of the Possible Molecular Targets of Pyrrolizidine Alkaloid Isoline-Induced Hepatotoxicity

Toxic Prediction of Pyrrolizidine Alkaloids and Structure-Dependent Induction of Apoptosis in HepaRG Cells

Pyrrolizidine Alkaloid-Induced Hepatotoxicity Associated with the Formation of Reactive Metabolite-Derived Pyrrole–Protein Adducts

Protein cross-linking in primary cultured mouse hepatocytes by dehydropyrrolizidine alkaloids: Structure–toxicity relationship

Hepatotoxicity and Tumorigenicity Induced by Metabolic Activation of Pyrrolizidine Alkaloids in Herbs.

Cytotoxicity of Pyrrolizidine Alkaloid in Human Hepatic Parenchymal and Sinusoidal Endothelial Cells: Firm Evidence for the Reactive Metabolites Mediated Pyrrolizidine Alkaloid-Induced Hepatotoxicity.

Seneciphylline, a Main Pyrrolizidine Alkaloid in Gynura Japonica, Induces Hepatotoxicity in Mice and Primary Hepatocytes Via Activating Mitochondria‐mediated Apoptosis

Metabolomic and Genomic Evidence for Compromised Bile Acid Homeostasis by Senecionine, A Hepatotoxic Pyrrolizidine Alkaloid

Genotoxicity of selected pyrrolizidine alkaloids in human hepatoma cell lines HepG2 and Huh6

Intestinal and Hepatic Biotransformation of Pyrrolizidine Alkaloid N-oxides to Toxic Pyrrolizidine Alkaloids

Potency ranking of pyrrolizidine alkaloids in metabolically competent human liver cancer cells and primary human hepatocytes using a genotoxicity test battery

Metabolic Activation of Pyrrolizidine Alkaloids: Insights into the Structural and Enzymatic Basis

Intracellular Glutathione Plays Important Roles in Pyrrolizidine Alkaloids-Induced Growth Inhibition on Hepatocytes.

Involvement of Bcl-xL degradation and mitochondrial-mediated apoptotic pathway in pyrrolizidine alkaloids-induced apoptosis in hepatocytes.

Utilization of a novel human hepatocyte-endothelial cell coculture model to determine differential toxicities of pyrrolizidine alkaloid food contaminants

First Evidence of Pyrrolizidine Alkaloid N-oxide-induced Hepatic Sinusoidal Obstruction Syndrome in Humans

Inhibition of Drp1 Protects Against Senecionine-Induced Mitochondria-Mediated Apoptosis in Primary Hepatocytes and in Mice